Legend Biotech Corporation (NASDAQ: LEGN) has been highlighted as an overlooked growth stock, demonstrating significant commercial success with its multiple myeloma therapy, CARVYKTI, which generated approximately $1.9 billion in sales for 2025. Notably, the therapy’s sales reached ~$555 million in Q4, contributing to the franchise’s profitability. The company expanded its manufacturing capabilities to treat 10,000 patients annually and increased collaboration revenue to $277.6 million. Additionally, the therapy’s global presence grew to 294 sites in 14 markets, and the company made strides in its R&D efforts by opening a new facility in Philadelphia. Despite this progress, some analysts suggest that other AI stocks may offer better investment potential.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://finance.yahoo.com/markets/stocks/articles/legend-biotech-legn-one-overlooked-154203702.html
